Holen Sie sich die Stockscreener-App
79.29
1.29%
1.01
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$78.28
Offen:
$78.05
24-Stunden-Volumen:
21.93M
Relative Volume:
1.41
Marktkapitalisierung:
$204.27B
Einnahmen:
$63.92B
Nettoeinkommen (Verlust:
$17.43B
KGV:
11.54
EPS:
6.87
Netto-Cashflow:
$17.04B
1W Leistung:
-1.28%
1M Leistung:
+4.25%
6M Leistung:
-19.37%
1J Leistung:
-38.05%
1-Tages-Spanne:
$77.10
$80.31
1-Wochen-Bereich:
$77.10
$82.44
52-Wochen-Spanne:
$73.31
$134.63
Merck Co Inc Stock (MRK) Company Profile
Firmenname
Merck Co Inc
Sektor
Telefon
908-740-4000
Adresse
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Vergleichen Sie MRK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
79.29 | 204.27B | 63.92B | 17.43B | 17.04B | 6.87 |
|
LLY
Lilly Eli Co
|
785.03 | 724.64B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
150.73 | 376.43B | 89.33B | 21.81B | 18.57B | 8.99 |
|
NVO
Novo Nordisk Adr
|
74.01 | 352.49B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
ABBV
Abbvie Inc
|
185.49 | 334.73B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
115.96 | 234.21B | 53.22B | 12.86B | 14.85B | 6.39 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-02-18 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-02-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-01-08 | Herabstufung | Truist | Buy → Hold |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-12-04 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-11 | Herabstufung | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-03-11 | Herabstufung | Societe Generale | Hold → Sell |
| 2024-01-04 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-27 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Hold |
| 2023-04-13 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-03-28 | Herabstufung | Societe Generale | Buy → Hold |
| 2023-03-13 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | Eingeleitet | Jefferies | Buy |
| 2023-02-22 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-10 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-14 | Hochstufung | Berenberg | Hold → Buy |
| 2022-07-06 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | Fortgesetzt | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-16 | Eingeleitet | Daiwa Securities | Neutral |
| 2021-12-13 | Herabstufung | UBS | Buy → Neutral |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-12-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-29 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-01 | Hochstufung | Argus | Hold → Buy |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-20 | Herabstufung | Argus | Buy → Hold |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-08-03 | Hochstufung | Goldman | Neutral → Buy |
| 2020-06-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-08-16 | Eingeleitet | SVB Leerink | Outperform |
| 2019-07-03 | Eingeleitet | Mizuho | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-05-13 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | Bestätigt | Citigroup | Buy |
| 2018-10-09 | Fortgesetzt | Guggenheim | Buy |
| 2018-04-23 | Hochstufung | Goldman | Neutral → Buy |
| 2018-04-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-03-12 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-07 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2018-01-16 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Merck Co Inc Aktie (MRK) Neueste Nachrichten
Why the Market Dipped But Merck (MRK) Gained Today - Yahoo
Merck (MRK) Gains as CDC Agenda Omits Gardasil Dose Changes - GuruFocus
Merck stock up as CDC meeting excludes HPV shots (MRK:NYSE) - Seeking Alpha
Merck (MRK) Expands Deals with Chinese Pharma Companies - GuruFocus
Kennedy's new US vaccine panel to discuss measles shot for children - marketscreener.com
Merck Stock Analysis: Is Today’s Massive 2% Spike a Breakout? - Daily Chhattisgarh News
Merck: Phase 3 trial in prostate cancer - MarketScreener
Merck Doses First Patient in Phase 3 Trial of Prostate Cancer Drug Candidate - MarketScreener
Merck (MRK) Begins Phase 3 Trial for New Prostate Cancer Treatment | MRK Stock News - GuruFocus
Breakthrough Prostate Cancer Drug Enters Phase 3 Trial: New Hope for 31% Survival Rate Disease - Stock Titan
2 Dividend Stocks to Buy and Never Sell - The Motley Fool
Dividend Growth Remains a Key Priority for Merck - Insider Monkey
Merck (MRK) Dips More Than Broader Market: What You Should Know - Nasdaq
Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer - CNBC
Supreme Court Decision Lets Fosamax Lawsuit Against Merck (MRK) Proceed - GuruFocus
Merck bid to stop Fosamax suit thwarted by Supreme Court - Seeking Alpha
Wall Street Bulls Look Optimistic About Merck (MRK): Should You Buy? - Nasdaq
Merck Manuals Launches AI-powered Search Tool, Providing Enhanced Access to Trusted Medical Information and Resources - PR Newswire
Goldman Sachs Remains a Buy on Merck & Co (MRK), Sets a $99.00 PT - Insider Monkey
Merck’s SWOT analysis: stock faces keytruda LOE challenge amid pipeline promise - Investing.com
Merck (MRK) Secures Landmark FDA Approval for Keytruda in Head and Neck Cancer - Daily Chhattisgarh News
Immuno-Oncology and Precision Medicine Trends Led by Merck & Pfizer Boost Gastric Cancer Market Growth - openPR.com
SpringWorks Therapeutics’ SWOT analysis: stock outlook amid Merck acquisition - Investing.com
RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit - AOL.com
Merck (MRK) Boosted by Rising MMR Vaccine Demand Amid Measles Outbreaks - GuruFocus
Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery - Benzinga
Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda - Investopedia
FDA Approves Merck's Keytruda for Head and Neck Cancer - GuruFocus
Merck's Keytruda gains additional indications in head and neck cancer - Seeking Alpha
Merck: FDA approves Keytruda for head and neck cancer - marketscreener.com
FDA Approves Merck's Anti-PD-1 Therapy - marketscreener.com
Merck Says FDA Approves Keytruda for Head and Neck Cancer With PD-L1 Expression - marketscreener.com
FDA Approves Merck's Keytruda for Specific Head and Neck Cancer | MRK Stock News - GuruFocus
Merck (MRK) Awaits EU Approval for New Pet Medicine - GuruFocus
Merck Animal Health Gets EU Positive Opinion for Numelvi Tablets for Dogs - marketscreener.com
Merck Animal Health Receives EU Cvmp Positive Opinion For Numelvi Tablets For Dogs - marketscreener.com
Merck (MRK) Awaits EU Approval for Innovative Canine Drug | MRK Stock News - GuruFocus
RFK Jr.’s New Vaccine Panel Includes Two Paid Witnesses Against Merck - Bloomberg.com
Merck Animal Health gets EU backing for Numelvi tablets (MRK:NYSE) - Seeking Alpha
Merck’s canine dermatitis drug Numelvi gets positive EU opinion - Investing.com
Merck (MRK) Animal Health Receives EU CVMP Positive Opinion for NUMELVI Tablets for Dogs - StreetInsider
Breakthrough: EU Panel Backs Merck's Novel Dog Itch Treatment That Works From Day One - Stock Titan
Kalkine : Is Merck Set for Strong Payouts This Dividend Season Dow Jones Industrial Average - Kalkine Media
Exclusive-Kennedy’s new vaccine adviser was expert witness against Merck vaccine - The Mighty 790 KFGO
Controversy Surrounds Merck (MRK) Due to Vaccine Litigation Ties - GuruFocus
RFK Jr’s vaccine advisor has worked against Merck shot (MRK) - Seeking Alpha
Exclusive-Kennedy's new vaccine adviser was expert witness against Merck vaccine - marketscreener.com
Merck (MRK) Initiates Late-Stage Dengue Vaccine Trial - GuruFocus
Merck: Phase 3 trial for dengue vaccine - marketscreener.com
Merck begins late-stage trial for single dose dengue vaccine - Seeking Alpha
Merck (MRK) Launches Key Phase 3 Trial for Dengue Vaccine | MRK Stock News - GuruFocus
Finanzdaten der Merck Co Inc-Aktie (MRK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Merck Co Inc-Aktie (MRK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Smart Dalton E. III | SVP Fin. - Global Controller |
Apr 30 '25 |
Option Exercise |
84.71 |
464 |
39,305 |
8,242 |
| Smart Dalton E. III | SVP Fin. - Global Controller |
May 02 '25 |
Option Exercise |
83.26 |
381 |
31,722 |
8,464 |
| Romanelli Joseph | President, Human Health Int?l |
May 02 '25 |
Option Exercise |
83.26 |
2,262 |
188,334 |
24,061 |
| Romanelli Joseph | President, Human Health Int?l |
Apr 30 '25 |
Option Exercise |
84.71 |
2,063 |
174,757 |
22,816 |
| Larson Betty D | EVP, Chief HR Officer |
Apr 30 '25 |
Option Exercise |
84.71 |
11,350 |
961,458 |
11,350 |
| Smart Dalton E. III | SVP Fin. - Global Controller |
Apr 25 '25 |
Option Exercise |
58.08 |
5,000 |
290,400 |
12,040 |
| Smart Dalton E. III | SVP Fin. - Global Controller |
Apr 25 '25 |
Sale |
82.76 |
4,262 |
352,723 |
7,778 |
0.39%
0.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):